IMVT
$38.02
Immunovant
($.41)
(1.07%)
IMVT
Earnings Whisper ®
N/A
2nd Quarter September 2020
Consensus:  ($0.32)
Revenue:  $0.00 Mil
Wednesday
Nov 11
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when IMVT reports earnings?
Beat
Meet
Miss

Where is IMVT's stock price going from here?
Up
Flat
Down
Stock chart of IMVT
Analysts
Summary of analysts' recommendations for IMVT
Score
Grade
Pivots
Resistance
$42.92
$41.61
$39.81

$38.50

Support
$36.70
$35.39
$33.59
Tweet
Growth
Description
Immunovant Inc. is a clinical-stage biopharmaceutical company focused on autoimmune diseases. The company's product candidate consists of IMVT-1401 which is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor which is in clinical stage. Immunovant Inc. is based in New York, United States.